{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:10:30Z","timestamp":1733058630047,"version":"3.30.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"DOI":"10.7759\/cureus.74902","type":"journal-article","created":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:42:23Z","timestamp":1733056943000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With Multiple Myeloma Treated With Elranatamab"],"prefix":"10.7759","author":[{"given":"Taku","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Kunisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis NJ","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, et al.. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023, 29:2570-6. 10.1038\/s41591-023-02589-w","journal-title":"Nat Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin AM","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al.. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023, 29:2259-67. 10.1038\/s41591-023-02528-9","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1276295","article-title":"Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case","volume":"14","author":"Mutlu YG","year":"2023","unstructured":"Mutlu YG, Y\u0131g\u0131t Kaya S, Maral S, Melek E, Baslar Z, Kaynar L, Sevindik OG. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. Front Immunol. 2023, 14:1276295. 10.3389\/fimmu.2023.1276295","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al.. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021, 384:705-16. 10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-b-cell maturation antigen chimeric antigen receptor t-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin T","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al.. Ciltacabtagene autoleucel, an anti-b-cell maturation antigen chimeric antigen receptor t-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023, 41:1265-74. 10.1200\/JCO.22.00842","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee DW","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al.. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019, 25:625-38. 10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"H. Ludwig","year":"2023","unstructured":"H. Ludwig, E. Terpos, N. van de Donk, et al.. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023, 24:255-69. 10.1016\/s1470-2045(23)00159-6","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW, et al.. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022, 387:495-505. 10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan M","year":"2024","unstructured":"Mohan M, Monge J, Shah N, et al.. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024, 14:35. 10.1038\/s41408-024-01003-z","journal-title":"Blood Cancer J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49192","article-title":"Exploring the high-grade and refractory neurotoxicity of teclistamab: an underreported entity","volume":"15","author":"Lutfi F","year":"2023","unstructured":"Lutfi F, Abdallah AO, Nashatizadeh M, et al.. Exploring the high-grade and refractory neurotoxicity of teclistamab: an underreported entity. Cureus. 2023, 15:e49192. 10.7759\/cureus.49192","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169836","article-title":"A systematic meta-analysis of cytokine release syndrome incidence in B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed and\/or refractory multiple myeloma","volume":"140","author":"S. Sharma","year":"2022","unstructured":"S. Sharma, D. Wang, H.-K Lon, et al.. A systematic meta-analysis of cytokine release syndrome incidence in B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed and\/or refractory multiple myeloma.  Blood. 2022, 140:10036-38. 10.1182\/blood-2022-169836","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant SJ","year":"2022","unstructured":"Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2022, 28:294-302. 10.1016\/j.jtct.2022.03.006","journal-title":"Transplant Cell Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/323642-severe-immune-effector-cell-associated-neurotoxicity-syndrome-in-a-patient-with-multiple-myeloma-treated-with-elranatamab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:42:24Z","timestamp":1733056944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/323642-severe-immune-effector-cell-associated-neurotoxicity-syndrome-in-a-patient-with-multiple-myeloma-treated-with-elranatamab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.74902","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}